Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2014

View Archived Issues

Scientists at University of North Carolina design novel Mer inhibitors

Vertex designs selective HSP inhibitors for neurodegenerative disorders

Synthetic MTDL as a novel therapeutic for ischemic stroke

Viral-induced overexpression of ITGA7 presented as a therapeutic approach for DMD

GSK's fluticasone plus umeclidinium combination safe in phase I trial

Bioequivalence study begins for Elite Pharmaceuticals' third opioid abuse deterrent drug

Clinical trial results presented for liraglutide for weight management and diabetes

Pharmaleads patents new mixed NEP/AP-N inhibitors

Novel dsRNA molecules divulged by PhaseRx

Genprex begins phase II trial of Oncoprex in lung cancer

Ceapro licenses dry powder formulation technology from University of Alberta

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical obtains Chinese clinical trial clearance

Terumo BCT and Kaneka collaborate on therapeutic apheresis and columns for LDL reduction

Cardio3 BioSciences enters agreement with ViroMed for use of C-Cathez in VM-202-CAD development

Proteo Biotech agrees to financing deal for orphan drug development

UCB invests in collaboration partner Beryllium

Sirona Biochem discloses cell protection agent

Japan Tobacco discloses new ROR-gamma antagonists

New BTK inhibitors patented by Roche

Japanese orphan drug designation for Edison's EPI-743 in Leigh syndrome

Summit reports results from phase Ib study of SMT-C1100 in pediatric DMD patients

GlycoMimetics receives payment from Pfizer in connection with phase III trial

aTyr Pharma completes first phase I study of Resokine

Baxter provides regulatory update on HyQvia

Antibe Therapeutics submits CTA for ATB-346

BioAlliance and Topotarget merge to form Onxeo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...